Chronic Myeloid Leukemia
Conditions
Brief summary
The tyrosine kinase inhibitor therapy (iTKs) is the first-line treatment of chronic myelogenous leukemia (CML). Its effectiveness in controlling the progression of the disease is such that it is possible today to consider stopping treatment in patients with deep molecular response (\> RM4.0). Only in about 50% of cases, patients relapse. It has been shown in these patients that hematopoietic stem cells (HSCs) are persistant, quiescent and insensitive to iTKs. These cells are probably at the origin of relapse. It is therefore necessary to develop complementary therapies to cure the disease and consider discontinuation iTKs The development of anti-tumor immunotherapy approach using genetically modified T cells to express a chimeric antigen receptor (CAR) and specifically targeting CML CSH + could address this issue. The membrane expression of the IL-1-RAP protein could be an interesting target.
Interventions
OTHERbiological samples
bone marrow and blood
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* patients for whom there is a strong suspicion of CML diagnosed as part of routine activity. * written informed consent
Exclusion criteria
* patient with atypical CML * patient with a non SMP CML * patients previously treated with interferon * patient enrolled in another study therapy or within the exclusion period thereof * pregnant or breast-feeding women * patient under guardianship, curator or under the protection of justice.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL1RAP protein expression on the surface of cells detected by flow cytometry | up to 2 years after inclusion |
Countries
France
Outcome results
None listed